CMS implements prescription payment plan

Oct. 2024Important Notices

Your Medicare patients with high drug costs may benefit from participating in the Medicare Prescription Payment Plan, which will be available beginning on Jan. 1, 2025.

As part of the Inflation Reduction Act (IRA), all Medicare drug plans and Medicare health plans with drug coverage (such as Medicare Advantage plans) will be required to offer the Medicare Prescription Payment Plan. This new program will allow plan members to make monthly payments toward their out-of-pocket prescription drug costs over the course of the plan year instead of paying all at once at a pharmacy. (For more information on the IRA, please visit the CMS webpage about the Inflation Reduction Act and Medicare.

The Medicare Prescription Payment Plan will be available starting on Jan. 1, 2025. Program participants will pay $0 at their pharmacy for covered Part D medications, and Part D plan sponsors will bill participants each month for any cost sharing they incur while in the program. Pharmacies will be paid in full by the Part D plan sponsor in accordance with Part D prompt payment requirements. For more information about the program, please visit the Medicare Prescription Payment Plan page.

Medicare plan members who are likely to benefit from this program will receive information about how to enroll this fall.

If you have any questions about this matter, please contact your physician account executive or call Provider Services at 1-866-918-1595. As always, thank you for the excellent care you provide to our members.


Recent Announcements

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Sep. 2026Education/Webinars

Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)

Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).
Sep. 2026Pharmacy Updates

Voluntary nationwide recall: Dextrose (Baxter – August 2026)

Baxter International Inc. is recalling one lot (lot Y495066) of 70% Dextrose Injection. Dextrose is used to replenish calories and fluid in certain situations.
Sep. 2026Pharmacy Updates